| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8836939 | Surgery | 2018 | 7 Pages |
Abstract
Despite having similar in vitro angiogenic activity, diabetic MSCs secrete a unique and inflammatory angiogenic signature that may influence MSC survival and function after transplantation in cell therapy applications. Strategies that normalize secretome in diabetic patients may improve the utility of autologous MSCs in this population of patients.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
Andrew D. Morris, Sidd Dalal, Haiyan Li, Luke P. Brewster,